Terns Pharmaceuticals, Inc.·4

Jan 6, 8:25 PM ET

Kuriakose Emil 4

4 · Terns Pharmaceuticals, Inc. · Filed Jan 6, 2026

Insider Transaction Report

Form 4
Period: 2026-01-02
Kuriakose Emil
Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2026-01-02$39.60/sh200$7,92051,320 total
  • Sale

    Common Stock

    2026-01-02$38.36/sh955$36,63250,365 total
Footnotes (3)
  • [F1]Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person.
  • [F2]This sale price represents the weighted average sale price of the shares sold ranging from $39.25 to $39.95 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]This sale price represents the weighted average sale price of the shares sold ranging from $38.25 to $38.73 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT